Hemlibra 105mg Injection: Effective Treatment for Hemophilia

Hemlibra 105mg Injection

Description:

• Contains the active constituent Emicizumab.
• Belongs to the class of medications called monoclonal antibodies.
• Used to treat patients with haemophilia A who have developed factor VIII inhibitors.
• Also indicated to treat severe haemophilia A who have not developed factor VIII inhibitors (the FVIII blood level is less than 1%).

Uses:

• Haemophilia A.

Therapeutic Effects:

• Binds to activated factor IX and factor X to restore function to the coagulation cascade and promote hemostasis.
• Restores the function of missing activated factor VIII, which is needed for effective blood clotting.
• Its structure differs from factor VIII; therefore, the medicine is unaffected by factor VIII inhibitors.

Interaction with other drugs:

• Inform your healthcare provider about all the medicines you take, including prescription medications, over-the-counter medications, nutritional and vitamin supplements, and herbal products.
• Certain medications interact with Hemlibra 105mg Injection and reduce its effectiveness by causing undesirable side effects.

Storage:

• Store in a refrigerator (2°C to 8°C).
• Do not freeze.
• Protect the medicine from light and excessive moisture.
• Keep the medicine out of reach of children and pets.

Administration:

• Given by injection under the skin (subcutaneous).
• Your doctor or nurse or other healthcare professional will show you how to inject the medicine.
• The recommended places to give an injection are the front of the waist (lower abdomen), upper outer arms, or the front of the thighs.
• For each injection, use a different area of the body than the one you used last time.

Safety Advices:

• Pregnancy: Do not take Hemlibra 105mg Injection if you are pregnant because this may harm the unborn baby.
• Breast feeding: Breastfeeding is not recommended in patients taking Hemlibra 105mg Injection.
• Lungs: Consult your doctor if you have any lung diseases before starting the treatment.
• Liver: Inform your physician if you have any liver diseases before initiating the treatment.
• Alcohol: Inform your physician if you are a chronic drinker.
• Driving: Hemlibra 105mg Injection does not affect your ability to drive and operate heavy machinery.

Side Effects:

• Common: Injection site reactions, joint pain, headache.
• Serious: Heart problems, muscle cramps and pain, blood clot, bleeding, destruction of red blood cells.

FAQs:

• Q 1. Can Hemlibra 105mg Injection be self-administered at home? Yes, Hemlibra 105mg Injection can be self-administered at home after proper training and instructions from a healthcare professional.
• Q 2. Can Hemlibra 105mg Injection be used in pediatric patients with hemophilia? Yes, Hemlibra 105mg Injection is approved for use in pediatric patients with hemophilia A.
• Q 3. Is Hemlibra 105mg Injection suitable for all types of hemophilia? Hemlibra 105mg Injection is specifically designed for the treatment of hemophilia A.
• Q 4. How is Hemlibra 105mg Injection administered? Hemlibra 105mg Injection is administered as a subcutaneous injection, generally, it is given once a week, every two weeks, or every four weeks, depending on the treatment plan determined by the healthcare provider.
• Q 5. What should I inform the physician before starting the treatment with Hemlibra 105mg Injection? Before you start using Hemlibra 105mg Injection, talk to your doctor and carefully follow their instructions on when to use a bypassing agent and the dose and schedule you should use.

Fact Box:

• Molecule name: Emicizumab.
• Therapeutic class: Antihemophilic agent.
• Pharmacological class: Bispecific monoclonal antibody.
• Indications: Haemophilia A.

Tags: diabetes, hemoglobin, injection, medical, medication, treatment, diabetes-management